I am a bit confused.. they already did this utility study in Oct 2021. Why repeat it? I also don't like the conclusion mentioned here about further studies. Is another economics study also needed?
Conclusion
PromarkerD could increase adoption of renoprotective interventions in patients at high risk for renal decline and lower the likelihood of aggressive treatment in those at low risk. Further studies are needed to assess patient outcomes with PromarkerD in real-world practice.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271740
3Q cash, hopefully enough time to release some positive news about FDA submission before cap raise, SP not looking healthy - Richard please be more transparent about what is going on with FDA & US rollout.
Ann: Clinical Utility Study demonstrates PromarkerD test benefits, page-5
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
76.0¢ |
Change
-0.010(1.30%) |
Mkt cap ! $99.56M | |||
| Open | High | Low | Value | Volume |
| 77.0¢ | 77.0¢ | 75.3¢ | $271.7K | 355.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 717 | 76.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 77.0¢ | 1298 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |